Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Stem Cell Therapies Make Steady Progress
Preclinical Development of ESC-, iPSC-, CSC-, and CLSC-Derived Products Moves Along Briskly
- Stem cells are many things to many people—a product of an errant procedure, the origin of cancer, a naturally occurring source of unlimited healing potential, a Frankenstein-like creation of virally infected cells, or a political football. CHI’s inaugural “Stem Cells in Drug Discovery and Development,” to be held ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.